(Q44178398)

30 November 2017

Lyme disease vaccination: are we ready to try again? (English)

1 reference

30 November 2017

0 references

Paul M Lantos

1

1 reference

30 November 2017

10 May 2013

1 reference

Lancet Infectious Diseases

30 November 2017

1 reference

30 November 2017

13

1 reference

30 November 2017

8

1 reference

30 November 2017

643-644

1 reference

Recombinant Outer Surface Protein A from Borrelia burgdorferi Induces Antibodies Protective against Spirochetal Infection in Mice

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

The cost-effectiveness of vaccination against Lyme disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

Cost-effectiveness analysis of the Lyme disease vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

The cost effectiveness of vaccinating against Lyme disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

The Clinical Assessment, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: Clinical Practice Guidelines by the Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

The rise and fall of the lyme disease vaccines: a cautionary tale for risk interventions in American medicine and public health

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

Vaccines against Lyme disease: What happened and what lessons can we learn?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

Tick-borne encephalitis 2010: epidemiology, risk areas, and virus strains in Europe and Asia-an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

Field effectiveness of vaccination against tick-borne encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

Conference report of the 10th meeting of the international scientific working group on tick-borne encephalitis (ISW-TBE): combating tick-borne encephalitis: vaccination rates on the rise

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

A campaign to increase the vaccination rate in a highly endemic tick-borne encephalitis region of Slovenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2813%2970085-9

7 January 2021

10.1016/S1473-3099(13)70085-9

Identifiers

DOI

1 reference

30 November 2017

1 reference

PubMed ID

23665340